Neoechinulin A

Research use only, not for human use.

Neoechinulin A has anti-inflammatory effect against LPS-stimulated RAW264.7 macrophages through inhibition of the NF-κB and p38 MAPK pathways.

Neoechinulin A has anti-inflammatory effect against LPS-stimulated RAW264.7 macrophages through inhibition of the NF-κB and p38 MAPK pathways, it may block the phosphorylation of mitogen-activated protein kinase (MAPK) molecule p38, apoptosis signal-regulating kinase 1 (ASK-1) and nuclear translocation of nuclear factor-κB (NF-κB) p65 and p50 subunits, it has a potential to be developed as a modulator of neuroinflammatory process in Alzheimer's disease.

Neoechinulin A (RAW264.7 macrophages; 3 hours; cells then stimulated with LPS (1 μg/mL) for 18 hours) suppresses PGE2, TNF-α, and IL-1β production in a dose-dependent manner.Neoechinulin A can suppress the production of pro-inflammatory mediators and cytokines including NO, PGE2, TNF-α, and IL-1β. Further, it reduced the expression of iNOS and COX-2 in LPS-stimulated RAW264.7 macrophages by inhibiting the NF-κB and p38 MAPK signaling pathways. Neoechinulin A suppresses amyloid-β oligomer-induced microglia activation and thereby protects PC-12 cells from inflammation-mediated toxicity.

In the Y-maze test, the intracerebroventicular (i.c.v.) administration of LPS (10 μg/mouse) significantly decreased spontaneous alternation behavior, which was prevented by the prior administration of neoechinulin A (300ng/mouse, i.c.v.).

——

Others

Other Targets

——

——

——

51551-29-2

323.4

C19H21N3O2

>98% (HPLC)

——

——

——

(-20℃)

With Ice Pack

≥ 2 years